230 related articles for article (PubMed ID: 38091986)
1. Integrated omics landscape of hepatocellular carcinoma suggests proteomic subtypes for precision therapy.
Xing X; Hu E; Ouyang J; Zhong X; Wang F; Liu K; Cai L; Zhou Y; Wang Y; Chen G; Li Z; Wu L; Liu X
Cell Rep Med; 2023 Dec; 4(12):101315. PubMed ID: 38091986
[TBL] [Abstract][Full Text] [Related]
2. Multiomics identifies metabolic subtypes based on fatty acid degradation allocating personalized treatment in hepatocellular carcinoma.
Li B; Li Y; Zhou H; Xu Y; Cao Y; Cheng C; Peng J; Li H; Zhang L; Su K; Xu Z; Hu Y; Lu J; Lu Y; Qian L; Wang Y; Zhang Y; Liu Q; Xie Y; Guo S; Mehal WZ; Yu D
Hepatology; 2024 Feb; 79(2):289-306. PubMed ID: 37540187
[TBL] [Abstract][Full Text] [Related]
3. Integrated Proteogenomic Characterization of HBV-Related Hepatocellular Carcinoma.
Gao Q; Zhu H; Dong L; Shi W; Chen R; Song Z; Huang C; Li J; Dong X; Zhou Y; Liu Q; Ma L; Wang X; Zhou J; Liu Y; Boja E; Robles AI; Ma W; Wang P; Li Y; Ding L; Wen B; Zhang B; Rodriguez H; Gao D; Zhou H; Fan J
Cell; 2019 Oct; 179(2):561-577.e22. PubMed ID: 31585088
[TBL] [Abstract][Full Text] [Related]
4. Molecular subtyping of hepatocellular carcinoma: A step toward precision medicine.
Wu Y; Liu Z; Xu X
Cancer Commun (Lond); 2020 Dec; 40(12):681-693. PubMed ID: 33290597
[TBL] [Abstract][Full Text] [Related]
5. The m6A methylation landscape stratifies hepatocellular carcinoma into 3 subtypes with distinct metabolic characteristics.
Shen X; Hu B; Xu J; Qin W; Fu Y; Wang S; Dong Q; Qin L
Cancer Biol Med; 2020 Nov; 17(4):937-952. PubMed ID: 33299645
[TBL] [Abstract][Full Text] [Related]
6. Reveal the molecular signatures of hepatocellular carcinoma with different sizes by iTRAQ based quantitative proteomics.
Wang Y; Liu H; Liang D; Huang Y; Zeng Y; Xing X; Xia J; Lin M; Han X; Liao N; Liu X; Liu J
J Proteomics; 2017 Jan; 150():230-241. PubMed ID: 27693406
[TBL] [Abstract][Full Text] [Related]
7. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
[TBL] [Abstract][Full Text] [Related]
8. Construction of a risk score prognosis model based on hepatocellular carcinoma microenvironment.
Zhang FP; Huang YP; Luo WX; Deng WY; Liu CQ; Xu LB; Liu C
World J Gastroenterol; 2020 Jan; 26(2):134-153. PubMed ID: 31969776
[TBL] [Abstract][Full Text] [Related]
9. Integrative multiomics analysis identifies molecular subtypes and potential targets of hepatocellular carcinoma.
Yang S; Zheng L; Li L; Zhang J; Wang J; Zhao H; Chen Y; Liu X; Gan H; Chen J; Yan M; He C; Li K; Ding C; Li Y
Clin Transl Med; 2024 Jun; 14(6):e1727. PubMed ID: 38804617
[TBL] [Abstract][Full Text] [Related]
10. Bidirectional deep neural networks to integrate RNA and DNA data for predicting outcome for patients with hepatocellular carcinoma.
Huang G; Wang C; Fu X
Future Oncol; 2021 Nov; 17(33):4481-4495. PubMed ID: 34374301
[TBL] [Abstract][Full Text] [Related]
11. Overweight/obesity-related transcriptomic signature as a correlate of clinical outcome, immune microenvironment, and treatment response in hepatocellular carcinoma.
Feng NN; Du XY; Zhang YS; Jiao ZK; Wu XH; Yang BM
Front Endocrinol (Lausanne); 2022; 13():1061091. PubMed ID: 36714595
[TBL] [Abstract][Full Text] [Related]
12. Supervised Learning and Multi-Omics Integration Reveals Clinical Significance of Inner Membrane Mitochondrial Protein (IMMT) in Prognostic Prediction, Tumor Immune Microenvironment and Precision Medicine for Kidney Renal Clear Cell Carcinoma.
Chen CC; Chu PY; Lin HY
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240154
[TBL] [Abstract][Full Text] [Related]
13. Multi-omics cluster defines the subtypes of CRC with distinct prognosis and tumor microenvironment.
Ma Y; Li J; Zhao X; Ji C; Hu W; Ma Y; Qu F; Sun Y; Zhang X
Eur J Med Res; 2024 Mar; 29(1):207. PubMed ID: 38549156
[TBL] [Abstract][Full Text] [Related]
14. Molecular classification of hepatocellular carcinoma: prognostic importance and clinical applications.
Raja A; Haq F
J Cancer Res Clin Oncol; 2022 Jan; 148(1):15-29. PubMed ID: 34623518
[TBL] [Abstract][Full Text] [Related]
15. Integrated Transcriptomic Analysis Revealed Hub Genes and Pathways Involved in Sorafenib Resistance in Hepatocellular Carcinoma.
Jiang X; Zhang W; Li L; Xie S
Pathol Oncol Res; 2021; 27():1609985. PubMed ID: 34737677
[TBL] [Abstract][Full Text] [Related]
16. Serine Protease Inhibitor Kazal Type 1, A Potential Biomarker for the Early Detection, Targeting, and Prediction of Response to Immune Checkpoint Blockade Therapies in Hepatocellular Carcinoma.
Jia J; Ga L; Liu Y; Yang Z; Wang Y; Guo X; Ma R; Liu R; Li T; Tang Z; Wang J
Front Immunol; 2022; 13():923031. PubMed ID: 35924241
[TBL] [Abstract][Full Text] [Related]
17. Identification of survival-related predictors in hepatocellular carcinoma through integrated genomic, transcriptomic, and proteomic analyses.
Dong F; Yang Q; Wu Z; Hu X; Shi D; Feng M; Li J; Zhu L; Jiang S; Bao Z
Biomed Pharmacother; 2019 Jun; 114():108856. PubMed ID: 30981109
[TBL] [Abstract][Full Text] [Related]
18. Prediction of Response to Sorafenib in Hepatocellular Carcinoma: A Putative Marker Panel by Multiple Reaction Monitoring-Mass Spectrometry (MRM-MS).
Kim H; Yu SJ; Yeo I; Cho YY; Lee DH; Cho Y; Cho EJ; Lee JH; Kim YJ; Lee S; Jun J; Park T; Yoon JH; Kim Y
Mol Cell Proteomics; 2017 Jul; 16(7):1312-1323. PubMed ID: 28550167
[TBL] [Abstract][Full Text] [Related]
19. Analysis of Liver Cancer Cell Lines Identifies Agents With Likely Efficacy Against Hepatocellular Carcinoma and Markers of Response.
Caruso S; Calatayud AL; Pilet J; La Bella T; Rekik S; Imbeaud S; Letouzé E; Meunier L; Bayard Q; Rohr-Udilova N; Péneau C; Grasl-Kraupp B; de Koning L; Ouine B; Bioulac-Sage P; Couchy G; Calderaro J; Nault JC; Zucman-Rossi J; Rebouissou S
Gastroenterology; 2019 Sep; 157(3):760-776. PubMed ID: 31063779
[TBL] [Abstract][Full Text] [Related]
20. Clinical and genomic landscape of hepatocellular carcinoma subtypes with various proportions of nonleukocyte stromal cells.
Peng J; Li C; Zhou J; Peng J; Wang C; Lai S; Guo S; Zhong Y; Deng L; Tang X
Gene; 2020 Nov; 761():145028. PubMed ID: 32763490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
